Evidence map›Paper›PMID 42780548›Full record

ArticleFrontiers in immunology2026

The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.

Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lan Zhang *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Mengshu You *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Bin YanDepartment of Biomedical Informatics, School of Life Sciences, Central South University, Changsha, Hunan, China.
Jian ZhangDepartment of Hematology, Xiangya Third Hospital, Central South University, Changsha, Hunan, China.
Yi YaoDepartment of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qingyan ZhangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zuozhong XieDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Shixiang WangDepartment of Biomedical Informatics, School of Life Sciences, Central South University, Changsha, Hunan, China.
Qian GaoDepartment of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sperm Autoantigenic Protein 17 (SPA17), a member of the cancer-testis antigen family, is frequently overexpressed in various malignancies, yet its biological functions, regulatory mechanisms, and clinical relevance in melanoma remain largely unexplored. This study aimed to investigate the expression pattern, prognostic value, and functional role of SPA17 in melanoma progression and immune modulation. Methods: We analyzed SPA17 expression in melanoma clinical specimens and correlated it with patient prognosis, metastatic burden, and immunotherapy response. Functional assays, including migration and proliferation tests, were performed in SPA17-knockdown melanoma cells Results: SPA17 was markedly upregulated in melanoma tissues, especially in metastatic lesions, and high expression correlated with poor prognosis, increased metastatic burden, and resistance to immunotherapy. Knockdown of SPA17 significantly suppressed melanoma cell migration in vitro and tumor growth Discussion: Collectively, our findings suggest that SPA17 promotes melanoma progression and immune evasion through upregulation of AXL, and that SPA17-directed peptide vaccination elicits antitumor immune responses and inhibits tumor growth. These data support SPA17 as a candidate prognostic biomarker and a potential therapeutic target warranting further clinical investigation.

Indexed as

AutoantigensCancer VaccinesMelanomaProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAnimalsAxl Receptor Tyrosine KinaseCell Line, TumorCell MovementHumansLymphocytes, Tumor-InfiltratingMaleMiceAutoantigensAxl Receptor Tyrosine KinaseCancer VaccinesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXLimmune evasionmelanomaSPA17tumor vaccine

Identifiers

PMID42780548
PMCPMC13597369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.